Idiopathic pulmonary fibrosis: moving forward

BMC Medicine

Luca Richeldi¹ 

[1] University of Southampton, Southampton, UK

关键词: Staging;    Epidemiology;    Patient-reported outcomes;    High-resolution computed tomography;    Interstitial lung disease;    Idiopathic pulmonary fibrosis;   

Others  :  1227201
DOI  :  10.1186/s12916-015-0481-6

 received in 2015-09-04, accepted in 2015-09-04,  发布年份 2015

【 摘 要 】

Idiopathic pulmonary fibrosis (IPF) is the prototype of a large and heterogeneous group of pulmonary disorders, mainly chronic and progressive, usually known as interstitial lung disease (ILD). Over the last few decades, IPF has been increasingly recognized as a major unmet medical need in respiratory medicine and has become the focus of intense research activity. This is due to the fact that IPF incidence is increasing worldwide, with rates (and unfortunately prognosis) which are very similar to those of many forms of cancer. Basic and clinical research on IPF has been enormously advancing over the last few decades, culminating in the recent discovery of two safe and effective drugs, now finally made available to patients. For all these reasons, missing a diagnosis of IPF is not acceptable anymore and there is a need for spreading the knowledge about IPF across various specialties of medicine globally. In this context, this article collection in BMC Medicine contributes to the ultimate goal of early identification and better management of patients with ILD, and IPF in particular, worldwide.

【 授权许可】

   
2015 Richeldi.

【 参考文献 】

• [1]Hutchinson J, Fogarty A, Hubbard R, McKeever T. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J. 2015; 46:795-806.
• [2]Raghu G, Rochwerg B, Zhang Y, Garcia CAC, Azuma A, Behr J et al.. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015; 192:e3-e19.
• [3]Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U et al.. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370:2071-82.
• [4]King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK et al.. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370:2083-92.
• [5]Mathai SK, Yang IV, Schwarz MI, Schwartz DA. Incorporating genetics into the identification and treatment of idiopathic pulmonary fibrosis. BMC Med. 2015. doi:. 10. 1186/s12916-015-0434-0 webcite
• [6]Bellaye P-S, Kolb M. Why do patients get IPF? Current concepts in pathogenesis of pulmonary fibrosis. BMC Med. 2015. doi:. 10. 1186/s12916-015-0412-6 webcite
• [7]Vancheri C. IPF and cancer: do they really look similar? BMC Med. 2015. doi:. 10. 1186/s12916-015-0478-1 webcite
• [8]Johannson KA, Ley B, Collard HR. Models of disease behaviour in idiopathic pulmonary fibrosis. BMC Med. 2015. doi:. 10. 1186/s12916-015-0403-7 webcite
• [9]Russell A-M, Sprangers MAG, Wibberley S, Snell N, Rose DM, Swigris JJ. The need for patient-centered clinical research in IPF. BMC Med. 2015. doi:. 10. 1186/s12916-015-0475-4 webcite
• [10]Fregonese L, Eichler I. The future of the development of medicines in IPF. BMC Med. 2015. doi:. 10. 1186/s12916-015-0480-7 webcite
• [11]Walsh SLF, Wells AU, Sverzellati N, Deveraj A, Von der Thusen J, Yousem SA, et al. Relationship between fibroblastic focus profusion and high resolution CT morphology in fibrotic lung disease. BMC Med. 2015. doi:. 10. 1186/s12916-015-0479-0 webcite